Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria | MicrobiomeTrials← Back to trialsNCT04513548
Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
TERMINATEDPHASE1INTERVENTIONAL
Trial Details
Start: 2020-08-05Est. Completion: 2022-07-19
Enrollment target: 11 participants Locations- Novartis Investigative Site, Berlin, Germany
Other microbiome trials you might be interested in
Urticaria Chronic
This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study …
Glenview, United StatesEst. completion Jun 2027
Chronic Inducible UrticariaChronic Spontaneous Urticaria
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinic…
Birmingham, United StatesEst. completion Dec 31, 2026
Phase 1
Recruiting
Chronic Spontaneous Urticaria
This is a Phase IIa, randomized, blinded, placebo controlled,Multiple-Ascending Dose study of BBT001 in adult patients w…
Wuhu, ChinaEst. completion Dec 31, 2027